Protein Biomarkers in Monocytes and CD4+ Lymphocytes for Predicting Lithium Treatment Response of Bipolar Disorder: a Feasibility Study with Tyramine-Based Signal- Amplified Flow Cytometry

Purpose

To determine if enhanced flow cytometry ( CellPrint™ ) can identify intracellular proteins of lithium responsiveness in monocytes and CD4 + lymphocytes from patients with bipolar disorder.

Methods

Eligible bipolar I or II patients were openly treated with lithium for 16-weeks. Baseline levels of Bcl2, BDNF, calmodulin, Fyn, phospho-Fyn/phospho-Yes, GSK3β, phospho-GSK3αβ, HMGB1, iNOS, IRS2, mTor, NLPR3, PGM1, PKA C-α, PPAR-γ, phospho-RelA, and TPH1 in monocytes and CD4 + lymphocytes of lithium responders and non-responders were measured with CellPrint™ . Their utility of discriminating responders from non-responders was explored. Protein-protein network and pathway enrichment analyses were conducted.

Results

Of the 24 intent-to-treat patients, 12 patients completed the 16-week study. Eleven of 13 responders and 8 of 11 non-responders were available for this analysis. The levels of the majority of analytes in lithium responders were lower than non-responders in both cell types, but only the level of GSK3β in monocytes was significantly different (p = 0.034). The combination of GSK3β and phospho-GSK3αβ levels in monocytes correctly classified 11/11 responders and 5/8 non-responders. Combination of GSK3β, phospho-RelA, TPH1 and PGM1 correctly classified 10/11 responders and 6/7 non-responders, both with a likelihood of ≥ 85%. Prolactin, leptin, BDNF, neurotrophin, and epidermal growth factor/epidermal growth factor receptor signaling pathways are involved in the lithium treatment response. GSK3β and RelA genes are involved in 4 of 5 these pathways.

Conclusion

CellPrint™ flow cytometry was able to detect differences in multiple proteins in monocytes and CD4 + lymphocytes between lithium responders and non-responders. A large study is warranted to confirm or refute these findings.